Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768439 | 0.90 | CHRM2 (0.39) | CHRM2TRPV4MCHR1HDAC6ADRB2 | |
| SCHEMBL768057 | 0.90 | TRPV4 (0.37) | CHRM2TRPV4MCHR1ADRB2CHRM3 | |
| SCHEMBL769264 | 0.90 | CHRM2 (0.39) | CHRM2TRPV4MCHR1HDAC6ADRB2 | |
| SCHEMBL768889 | 0.90 | CHRM2 (0.39) | CHRM2TRPV4MCHR1HDAC6ADRB2 | |
| SCHEMBL769390 | 0.85 | TRPV4 (0.36) | TRPV4HDAC6ADRB2CHRM3SIRT5 | |
| SCHEMBL768531 | 0.85 | HTR4 (0.36) | TRPV4ADRB2CHRM3DRD2SLC2A1 | |
| SCHEMBL768562 | 0.85 | MCHR1 (0.41) | CHRM2TRPV4MCHR1HDAC6ADRB2 | |
| SCHEMBL379962 | 0.84 | CHRM2 (0.56) | CHRM2CHRM3SLC2A1 | |
| SCHEMBL769140 | 0.84 | CHRM2 (0.36) | CHRM2MCHR1ADRB2CHRM3HTR1A | |
| SCHEMBL768337 | 0.84 | CHRM3 (0.42) | CHRM2HDAC6CHRM3SIRT5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | CHRM2 2/4885TRPV4 308/4885MCHR1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.